Differences in antibody response to whole-cell pertussis vaccines

K. M. Edwards, M. D. Decker, Neal A Halsey, B. A. Koblin, T. Townsend, B. Auerbach, D. T. Karzon

Research output: Contribution to journalArticle

Abstract

It has been assumed that whole-cell pertussis vaccines (WCVs) commercially distributed in the United States are of comparable immunogenicity, as all must comply with established standards for licensure. However, we have recently noted significant differences in antibody responses between groups of infants receiving the two WCVs commercially available in the United States. In separate studies performed concurrently under similar protocols at Vanderbilt and Johns Hopkins universities, infants were randomized to receive either an acellular pertussis vaccine or WCV. The acellular pertussis vaccine used at the two sites was identical, but the WCVs were from different manufacturers. Antibody responses to acellular pertussis vaccine did not differ between the two studies; responses to WCV differed dramatically, with infants receiving the Lederle WCV producing a 46-fold increase in antibody to pertussis toxin, compared with a 2.4-fold increase for infants receiving the Connaught WCV (P = .00003). Evaluation of other comparative data sets that were available provided further support for the conclusion that the two commercially available WCVs consistently differed in their ability to induce antibody to pertussis toxin. These findings have important implications for the design and interpretation of clinical trials comparing acellular and WCV products.

Original languageEnglish (US)
Pages (from-to)1019-1023
Number of pages5
JournalPediatrics
Volume88
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Pertussis Vaccine
Antibody Formation
Acellular Vaccines
Pertussis Toxin
Antibodies
Licensure

Keywords

  • immunization
  • pertussis
  • whole-cell vaccines

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Edwards, K. M., Decker, M. D., Halsey, N. A., Koblin, B. A., Townsend, T., Auerbach, B., & Karzon, D. T. (1991). Differences in antibody response to whole-cell pertussis vaccines. Pediatrics, 88(5), 1019-1023.

Differences in antibody response to whole-cell pertussis vaccines. / Edwards, K. M.; Decker, M. D.; Halsey, Neal A; Koblin, B. A.; Townsend, T.; Auerbach, B.; Karzon, D. T.

In: Pediatrics, Vol. 88, No. 5, 1991, p. 1019-1023.

Research output: Contribution to journalArticle

Edwards, KM, Decker, MD, Halsey, NA, Koblin, BA, Townsend, T, Auerbach, B & Karzon, DT 1991, 'Differences in antibody response to whole-cell pertussis vaccines', Pediatrics, vol. 88, no. 5, pp. 1019-1023.
Edwards KM, Decker MD, Halsey NA, Koblin BA, Townsend T, Auerbach B et al. Differences in antibody response to whole-cell pertussis vaccines. Pediatrics. 1991;88(5):1019-1023.
Edwards, K. M. ; Decker, M. D. ; Halsey, Neal A ; Koblin, B. A. ; Townsend, T. ; Auerbach, B. ; Karzon, D. T. / Differences in antibody response to whole-cell pertussis vaccines. In: Pediatrics. 1991 ; Vol. 88, No. 5. pp. 1019-1023.
@article{498f9bdc88eb408a80cceb495f7c0c8a,
title = "Differences in antibody response to whole-cell pertussis vaccines",
abstract = "It has been assumed that whole-cell pertussis vaccines (WCVs) commercially distributed in the United States are of comparable immunogenicity, as all must comply with established standards for licensure. However, we have recently noted significant differences in antibody responses between groups of infants receiving the two WCVs commercially available in the United States. In separate studies performed concurrently under similar protocols at Vanderbilt and Johns Hopkins universities, infants were randomized to receive either an acellular pertussis vaccine or WCV. The acellular pertussis vaccine used at the two sites was identical, but the WCVs were from different manufacturers. Antibody responses to acellular pertussis vaccine did not differ between the two studies; responses to WCV differed dramatically, with infants receiving the Lederle WCV producing a 46-fold increase in antibody to pertussis toxin, compared with a 2.4-fold increase for infants receiving the Connaught WCV (P = .00003). Evaluation of other comparative data sets that were available provided further support for the conclusion that the two commercially available WCVs consistently differed in their ability to induce antibody to pertussis toxin. These findings have important implications for the design and interpretation of clinical trials comparing acellular and WCV products.",
keywords = "immunization, pertussis, whole-cell vaccines",
author = "Edwards, {K. M.} and Decker, {M. D.} and Halsey, {Neal A} and Koblin, {B. A.} and T. Townsend and B. Auerbach and Karzon, {D. T.}",
year = "1991",
language = "English (US)",
volume = "88",
pages = "1019--1023",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Differences in antibody response to whole-cell pertussis vaccines

AU - Edwards, K. M.

AU - Decker, M. D.

AU - Halsey, Neal A

AU - Koblin, B. A.

AU - Townsend, T.

AU - Auerbach, B.

AU - Karzon, D. T.

PY - 1991

Y1 - 1991

N2 - It has been assumed that whole-cell pertussis vaccines (WCVs) commercially distributed in the United States are of comparable immunogenicity, as all must comply with established standards for licensure. However, we have recently noted significant differences in antibody responses between groups of infants receiving the two WCVs commercially available in the United States. In separate studies performed concurrently under similar protocols at Vanderbilt and Johns Hopkins universities, infants were randomized to receive either an acellular pertussis vaccine or WCV. The acellular pertussis vaccine used at the two sites was identical, but the WCVs were from different manufacturers. Antibody responses to acellular pertussis vaccine did not differ between the two studies; responses to WCV differed dramatically, with infants receiving the Lederle WCV producing a 46-fold increase in antibody to pertussis toxin, compared with a 2.4-fold increase for infants receiving the Connaught WCV (P = .00003). Evaluation of other comparative data sets that were available provided further support for the conclusion that the two commercially available WCVs consistently differed in their ability to induce antibody to pertussis toxin. These findings have important implications for the design and interpretation of clinical trials comparing acellular and WCV products.

AB - It has been assumed that whole-cell pertussis vaccines (WCVs) commercially distributed in the United States are of comparable immunogenicity, as all must comply with established standards for licensure. However, we have recently noted significant differences in antibody responses between groups of infants receiving the two WCVs commercially available in the United States. In separate studies performed concurrently under similar protocols at Vanderbilt and Johns Hopkins universities, infants were randomized to receive either an acellular pertussis vaccine or WCV. The acellular pertussis vaccine used at the two sites was identical, but the WCVs were from different manufacturers. Antibody responses to acellular pertussis vaccine did not differ between the two studies; responses to WCV differed dramatically, with infants receiving the Lederle WCV producing a 46-fold increase in antibody to pertussis toxin, compared with a 2.4-fold increase for infants receiving the Connaught WCV (P = .00003). Evaluation of other comparative data sets that were available provided further support for the conclusion that the two commercially available WCVs consistently differed in their ability to induce antibody to pertussis toxin. These findings have important implications for the design and interpretation of clinical trials comparing acellular and WCV products.

KW - immunization

KW - pertussis

KW - whole-cell vaccines

UR - http://www.scopus.com/inward/record.url?scp=0026052745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026052745&partnerID=8YFLogxK

M3 - Article

C2 - 1945605

AN - SCOPUS:0026052745

VL - 88

SP - 1019

EP - 1023

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -